A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Eclipse plunges Guardant into darkness
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.